Loading...
•
Sep 30, 2024
Emergent BioSolutions Q3 2024 Earnings Report
Emergent BioSolutions' financial position strengthened in Q3 2024, marked by increased revenue, net income, and adjusted EBITDA, and the company raised its FY 2024 guidance.
Key Takeaways
Emergent BioSolutions reported a strong Q3 2024 with a 9% increase in total revenues to $293.8 million and a 144% increase in net income to $114.8 million compared to the prior year. Adjusted EBITDA also saw a significant rise of 432% to $105.3 million. The company has raised its full-year 2024 guidance, reflecting improved financial performance and strategic progress.
Total revenues for Q3 2024 increased by 9% year-over-year, reaching $293.8 million.
Net income for Q3 2024 saw a substantial increase of 144% compared to the previous year, amounting to $114.8 million.
Adjusted EBITDA for Q3 2024 increased by 432% year-over-year, totaling $105.3 million.
The company raised its full-year 2024 financial guidance, indicating improved expectations for future performance.
Emergent BioSolutions
Emergent BioSolutions
Emergent BioSolutions Revenue by Segment
Revenue by Segment
Anthrax MCM Revenue
CapyFin.comSmallpox MCM Revenue
CapyFin.comOther Products Revenue
CapyFin.com Forward Guidance
Emergent BioSolutions updated its financial forecast for full year 2024, anticipating total revenues between $1,065 million and $1,125 million, a net loss between $(203) million and $(183) million, adjusted EBITDA between $180 million and $200 million, and total segment adjusted gross margin between 43% and 45%.
Positive Outlook
- Total revenues are projected to be between $1,065 million and $1,125 million.
- Adjusted EBITDA is expected to range from $180 million to $200 million.
- Total segment adjusted gross margin is forecasted to be between 43% and 45%.
- R&D expenditure is estimated to be approximately 7% of revenue.
- Capital expenditures are projected to be around $25 million.
Challenges Ahead
- Net loss is forecasted to be between $(203) million and $(183) million.
- Adjusted net loss is projected to be between $(50) million and $(30) million.
- Interest expense is expected to be approximately $75 million.
- Depreciation and amortization are estimated to be around $109 million.
- Commercial Products revenue is expected to be between $420 million and $430 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income